论文部分内容阅读
本实验采用放免分析法测定了１５例慢性喘息型支气管炎（简称喘支）、１４例支气管哮喘（简称哮喘）发作期病人血浆生物活性肽ＳＰ、ＶＩＰ、ＥＴ—１含量并以１５例正常健康人为正常对照组。结果表明，哮喘和喘支患者血浆ＳＰ、ＥＴ—１含量明显高于对照组。哮喘患者血浆ＶＩＰ含量明显低于对照组。哮喘和喘支患者血浆ＳＰ、ＶＩＰ、ＥＴ—１含量也不同。提示：ＳＰ、ＶＩＰ、ＥＴ—１在哮喘和喘支发病中代谢不同，可能参与哮喘和喘支的病理过程。
In this study, radioimmunoassay was used to determine the content of plasma bioactive peptides SP, VIP and ET-1 in 15 patients with chronic asthmatic bronchitis (asthma) and 14 patients with bronchial asthma (asthma) and 15 healthy controls Human normal control group. The results showed that asthma and asthma patients with plasma SP, ET-1 levels were significantly higher than the control group. The plasma VIP level of asthmatic patients was significantly lower than that of the control group. Asthma and asthma patients with plasma SP, VIP, ET-1 content is also different. Tip: SP, VIP, ET-1 metabolism in the pathogenesis of asthma and asthma are different, may be involved in the pathological process of asthma and asthma.